Journal
ACTA PHARMACOLOGICA SINICA
Volume 34, Issue 6, Pages 747-754Publisher
ACTA PHARMACOLOGICA SINICA
DOI: 10.1038/aps.2013.50
Keywords
mesenchymal stem cell; cell therapy; tissue injury; degenerative disease; immune disorder; graft-versus-host disease; immunomodulation; trophic factor
Funding
- Key Basic Research Project of China [2011CB966200, 2010CB945600, 2011CB965100]
- Key Project of the National Natural Science Foundation of China [81030041]
- National Natural Science Foundation of China [31171321, 81101622]
- Special Funds for the National Key Sci-Tech Special Project of China [2012ZX10002-016, 2012ZX10002011-011]
- Shanghai Science and Technology Committee [11ZR1449500, 12ZR1439800]
- Science Fund for Creative Research Groups, NSFC, China [81221061]
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs), the major stem cells for cell therapy, have been used in the clinic for approximately 10 years. From animal models to clinical trials, MSCs have afforded promise in the treatment of numerous diseases, mainly tissue injury and immune disorders. In this review, we summarize the recent opinions on methods, timing and cell sources for MSC administration in clinical applications, and provide an overview of mechanisms that are significant in MSC-mediated therapies. Although MSCs for cell therapy have been shown to be safe and effective, there are still challenges that need to be tackled before their wide application in the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
